Debra Hughes, MS, Author at MPR - Page 40 of 40

Debra Hughes, MS

All articles by Debra Hughes, MS

Diversity of Genetic and Epigenetic Events Leading to Malignant Transformation: Unifying Themes for the Effective Management of Solid Tumor and Hematologic Malignancies

The ASH/ASCO Joint Symposium, held today at the 52nd American Society of Hematology Annual Meeting and Exposition, focused on the understanding of the various genetic and epigenetic events that lead to malignant transformation and solid tumor/hematologic malignancies and discussed novel therapies that selectively target those events.

Oral Lenalidomide, Cyclophosphamide, and Prednisone (RCP): Preliminary Results Suggest “Excellent” Activity in Patients With Newly Diagnosed Multiple Myeloma

Initial analysis of the first evaluable patients with newly diagnosed multiple myeloma enrolled in a phase 2 study has found the combination of lenalidomide, cyclophosphamide, and prednisone (RCP) to have “excellent” activity, with manageable overall toxicities. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

“Excellent Outcomes” Reported for Patients With Follicular Lymphoma (FL) Treated Front-Line With Rituximab, Cyclophosphamide, Vincristine, Prednisone + 2 Years of Rituximab Maintenance

Patients with follicular lymphoma who receive initial treatment with rituximab, cyclophosphamide, vincristine, and prednisone (R-CVP) followed by 2 years of maintenance with rituximab had outcomes that compared favorably with more intensive combinations, results of a retrospective population-based analysis using the British Columbia (BC) Cancer Agency Lymphoid Cancer Database has found. The study was presented at the 52nd American Society of Hematology Annual Meeting and Exposition.

Multivariate Analysis of Response and Survival After Treatment With Clofarabine, Cytarabine, and G-CSF Priming (GCLAC) in Relapsed/Refractory Acute Myeloid Leukemia: Comparison With Prior Experience Using Fludarabine and Cytarabine Combination Regimens

Pamela S. Becker, MD, PhD, at University of Washington in Seattle, Wash., and colleagues conducted a study that indicated priming with clofarabine, cytarabine, and granulocyte colony-stimulating factor (G-CSF) (GCLAC) is active in relapsed and refractory acute myeloid leukemia (AML). Results of this study were presented at the 52nd American Society of Hematology Meeting and Exposition.